Company Overview and News

How proptech is changing Hong Kong’s property industry

2018-05-16 scmp
Start-ups in Asia-Pacific have received US$4.8b, or over 60pc of the world’s proptech investments, with Hong Kong and China taking US$3b of that amount

Hong Kong’s Swire Properties in talks to sell two office towers in city’s east

2018-05-10 scmp
The company is putting the Cityplaza Three and Cityplaza Four towers on the market amid strong demand for office space in the city

Swire Properties’ first-quarter malls sales post increases as tourists returned to Hong Kong

2018-05-04 scmp
Swire Properties said retail sales at the shopping malls under its management gained in the first three months of the year, as increasing tourist arrivals spilled over to higher shopping bills.

Pop-up stores to increase in Hong Kong as rents for retail space continue to rise

2018-05-01 scmp
Analysts say pop-up stores allow retailers and mall operators to gather customers’ response quickly and adjust their business plans to capture opportunities

Swire Properties Ltd. ADR 2017 Q4 - Results - Earnings Call Slides

2018-03-16 seekingalpha
The following slide deck was published by Swire Properties Ltd. ADR in conjunction with their 2017 Q4 earnings call.

Swire Pacific profit up by a half as property sales offset losses from aviation, marine services

2018-03-15 scmp
Underlying profit of HK$4.74 billion last year was still lower than the HK$5.27 billion forecast by analysts

How Hong Kong can be the bridge to the world for mainland China’s green bond market

2018-03-12 scmp
City launches a certification scheme for green bonds amid calls for it to use its expertise in financial services to help develop the market

Look east: MNCs find Hong Kong’s alternate CBD to Central

2018-03-07 scmp
A total of 63 Fortune 500 companies occupy about 2.2m sq ft of office spaces in Hong Kong East

Swire Properties takes stake in venture to gain foothold in Shanghai’s rising commercial district

2018-02-26 scmp
The company has agreed to take a 50 per cent interest in a Shanghai retail development project in Pudong for US$214m

From Coca-Cola to Cathay Pacific, Swire Pacific’s five major businesses in Hong Kong

2018-02-09 scmp
Started in 1870 as a small branch of its UK parent, Swire Pacific is a major player in property, beverages, aviation, marine services and trading and industries

Cathay Pacific and offshore marine business will test incoming Swire chairman

2018-02-09 scmp
Analysts say the task has been cut out for Merlin Bingham Swire, who takes over as chairman of the group’s Asian holding unit and property subsidiary on July 1

Swire looks to founder’s scion to steer the trading, property units out of their earnings doldrums

2018-02-08 scmp
John Slosar, who will retire from the Swire Group on July 1, will remain as chairman of Cathay Pacific Airways to guide the carrier’s transformation plan.

Swire Properties tops out latest office tower in Hong Kong’s new ‘eastern CBD’

2018-02-02 scmp
Multinationals are moving out of Central Hong Kong in their droves in search of twice the spec, at half the cost

Possibilities of collaboration with start-ups bring big companies to co-working spaces in Hong Kong

2018-01-31 scmp
Firms are leaving Central for the city’s outer areas in pursuit of digitalisation, millennial talent and cost benefits

Want to beat Hong Kong’s sky-high office rents? Try co-working spaces that cost three times less

2018-01-08 scmp
Shared space can be a viable alternative for companies in the world’s most expensive location for conventional offices, according to research

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...